June 2014

In This Issue

A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

BVGH will celebrate its ten year anniversary this month at the 2014 BIO International Convention in San Diego. BIO is sure to be as meaningful as ever, and will feature keynote speakers Hillary Clinton, Richard Branson, Francis Gurry (WIPO), and BVGH Board members, James Greenwood and Steven Burrill.

BVGH will be managing several important events this year at the 2014 BIO International Convention. I will be moderating two panel sessions, including Africa: The Next Biotech Frontier? and The Changing Landscape of Industry's Engagement in Global Health. WIPO Director General, Francis Gurry, will be giving the Intellectual Property Session keynote lecture and participating on the Scientific American Panel, as well as speaking to CEOs and Executives at a private session co-hosted by BIO and BVGH.

Another important event will also occur this month. The Washington Biotechnology and Biomedical Association (WBBA) is hosting the 2014 Life Sciences Innovation Northwest conference (LSINW) in Seattle. This event is North America’s largest, fully-integrated, life science expo.

Roopa Ramamoorthi, Katy Graef, and I will be at the 2014 BIO International Convention; we look forward to meeting you there as well as in Seattle at the LSINW conference!

I am pleased to welcome our two newest WIPO Re:Search Members, the University of Edinburgh and the University of Yaoundé I.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

Special Notice
The 2014 Biotechnology Industry Organization (BIO) International Convention will be held June 23-26, in San Diego, California. WIPO Re:Search will be highlighted in the following panel sessions, moderated by Jennifer Dent:

**The Changing Landscape of Industry’s Engagement in Global Health** (June 25th, 2014, 8:30am - 10:00am)

Participants:
Robert DeBerardine, Senior Vice President & General Counsel, Sanofi
Charlotte Hubbert, Program Investment Officer, Venture Investing, Bill & Melinda Gates Foundation
Charles Magness, President & CEO, Kineta, Inc.
David Olsen, Head of External Partnerships Infectious Disease, MSD*
Fred Tonelli, Head of External Innovation, Global Public Health, Johnson & Johnson's Janssen R&D

**Africa: The Next Biotech Frontier?** (June 25th, 10:15am - 11:45am)

Participants:
Richard Gordon, Director, Strategic Health Innovation Partnerships (SHIP), MRC South Africa
Dennis Liotta, Samuel Chandler Dobbs Professor of Chemistry, Emory University
Solomon Nwaka, Director, African Network for Drugs and Diagnostics Innovation (ANDI), World Health Organization
Mmboneni Muofhe, Deputy Director General, Technology Innovation, Dept. of Science and Technology, South Africa Nigerian National Universities Commission (NUC) Representative

*Known as Merck in the US and Canada

**WIPO Re:Search Statistics**

Cornerstones of Collaboration

Three new partnerships were finalized this month, including:

Alnylam will provide Aberystwyth University with lipophilic in vivo siRNA delivery reagents, which will be used by researchers at Aberystwyth University to examine the effect of gene knockdown in schistosome worms.

**New Member Announcement**

We are pleased to announce that the University of Edinburgh and the University of Yaoundé I have joined WIPO Re:Search.
The University of Edinburgh, located in Scotland, United Kingdom, is home to the Edinburgh Infectious Diseases (EID) network. The EID includes over 150 Principal Investigators and 760 active researchers across the field of infectious disease. Research projects within the EID include the immunology of helminth infections, malaria pathogenesis and vaccines, and disease progression in trypanosome infections.

Located in Yaoundé, Cameroon, the University of Yaoundé I has eight departments within its Faculty of Medicine and Biomedical Sciences, including the Centre for Implementation and Community-Based Research (CICBR) and the Laboratory of Bioorganic and Medicinal Chemistry (LABIOMED). Research at the University includes examining the antibacterial, anti-malarial, and anti-trypanosomal activities of natural products.

**Partnership Hub Central**

Tom Bombelles, Head, Global Health, WIPO, presented WIPO Re:Search and chaired a panel on Open Innovation at the International Society for Neglected Tropical Diseases' (ISNTD) Drug Discovery and Development (ISNTD d3) meeting in London. The conference attracted an impressive group of scientists committed to NTD research, including researchers from seven WIPO Re:Search Members. WIPO's participation served to raise awareness of the Consortium, and also to recruit new Members.

Katy Graef gave a presentation introducing global health, WIPO Re:Search, and diagnostic platforms developed to address diseases.
of the developing world at the University of Washington Bioengineering department weekly seminar.

Katy presents global health measurements at the University of Washington.

Member Spotlight

Olfat Hammam, Professor of Pathology, Theodor Bilharz Research Institute (TBRI), finished her one-year sabbatical at Stanford University in the laboratory of Michael Hsieh, Assistant Professor of Urology. Her research project, which focused on schistosomal bladder carcinogenesis and fibrosis, culminated in the acceptance of two articles for publication. Their PLOS NTDs article can be found here and their Trends in Parasitology article can be found here. Congratulations Olfat, Michael, and the Hsieh lab!
Highlighted Contributions

Featured this month are two contributions submitted by Sanofi to the WIPO Re:Search Database.

**Eflornithine samples for R&D purpose (ID: 1361)**
Sanofi can provide Members with information regarding Eflornithine, including clinical and pharmacological data, as well as samples for R&D. Eflornithine is a WHO-recommended treatment for human African trypanosomiasis (HAT).

**Erythromycin compounds, their process of preparation, and their application as medicaments (ID: 1204)**
Sanofi can provide the patents related to erythromycin compounds - macrolides with antibiotic properties. These patents include the compounds’ process of preparation as well as experimental data.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

WIPO Re:Search in the News

Jennifer Dent was quoted in a recent press release from WIPO Re:Search Member, Kineta, Inc. The release announced new data demonstrating activity of Kineta's innate immune response agonist against dengue virus serotype 2 in vivo. These agonists, which target IRF-3, have the potential to inhibit a diverse range of viruses.

WIPO Re:Search was mentioned in the 2014 Special 301 Report published by the United States Trade Representative. The Report, which presents the state of intellectual property rights (IPR) worldwide, briefly describes WIPO Re:Search within its "Best IPR Practices by Trading Partners" subsection.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 23-26</td>
<td>2014 BIO International Convention</td>
<td>San Diego, CA</td>
<td>Website</td>
</tr>
<tr>
<td>June 30 - July 2</td>
<td>Seventh EDCTP Forum - The Partnership Journey: New Horizon for Better Health</td>
<td>Berlin, Germany</td>
<td>Website</td>
</tr>
<tr>
<td>July 13 - 18</td>
<td>Gordon Conference: An Interdisciplinary Approach to Tackling Drug Resistance Across Disease States</td>
<td>Newry, ME</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event? Do you have a Research Request to highlight in the Snapshot? We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members
*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

This email was sent to jdent@bvgh.org by jdent@bvgh.org | Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109